Polymeric Nanoparticles for Inhibitory RNA Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current delivery systems for inhibitory RNAs, such as siRNA, face challenges in achieving high concentrations, controlled, and sustained release, especially for intracellular delivery, due to degradation by endogenous nucleases and immune responses, and are limited by toxicity and rapid clearance from systemic applications.
Innovation Solution
Polymeric nanoparticles encapsulating inhibitory RNAs, complexed with polycations, are developed to enhance encapsulation efficiency and facilitate controlled, sustained release, allowing deep tissue penetration and intracellular delivery by modifying the nanoparticle surface with coupling agents for modular assembly and disassembly of functional elements.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If viral vectors are used for gene delivery, then delivery efficiency is improved, but safety concerns arise due to potential immune responses and rapid clearance
Solution Approach 1:
The patent employs nonviral polymeric nanoparticles as temporary, non-integrating delivery vehicles that degrade safely in the body, avoiding the persistent immune activation and integration risks associated with viral vectors. The polymeric nature allows for safe degradation products and no genomic integration, resolving the safety concerns while maintaining delivery function.
Solution Approach 2:
The patent modifies the delivery system by changing from viral-based to polymeric nanoparticle-based delivery, altering fundamental parameters of the delivery vehicle (material composition, size control, surface properties) to achieve both efficiency and safety. The polymeric nanoparticles can be engineered with specific molecular weights, surface charges, and degradation rates to optimize both delivery and safety profiles.
2Productivity
If cationic liposome complexes are used for gene delivery, then nonviral delivery is achieved, but toxicity increases especially to mucosal epithelium
Solution Approach 1:
The patent applies local quality by creating nanoparticles with specific surface properties (charge, hydrophobicity, functional groups) that can be tailored for different tissue targets. The nanoparticle surface can be modified with specific ligands or charges to enhance uptake in certain tissues while reducing toxicity in others, particularly mucosal epithelium, through localized interaction mechanisms.
Solution Approach 2:
The patent uses composite polymeric materials with varying compositions, crosslinking densities, and functional groupings to create nanoparticles that balance delivery capability with reduced toxicity. The composite nature allows incorporation of different polymers with complementary properties to achieve both effective delivery and reduced harmful effects on sensitive tissues.
3Ease of manufacture
If inhibitory RNAs are administered naked, then simplicity is maintained, but degradation by endogenous nucleases occurs
Solution Approach 1:
The patent embeds inhibitory RNAs inside polymeric nanoparticle cores, creating a nested structure where the RNA is protected within the nanoparticle matrix. This nesting provides physical protection from nucleases while maintaining the ability to deliver the RNA to target cells. The RNA remains intact during circulation and is released only at the target site.
Solution Approach 2:
The polymeric nanoparticle acts as an intermediary carrier between the inhibitory RNA and the target cell. This intermediary protects the RNA from degradation during transit through bodily fluids and facilitates controlled release at the target site, bridging the gap between simple administration and protected delivery.
4Ease of manufacture
If lipoplexes are used for RNA delivery, then formulation is easy, but controlled or sustained release is not achieved
Solution Approach 1:
The patent introduces dynamic control over release timing and duration through polymeric nanoparticle design. The nanoparticles can be engineered with controllable degradation rates, crosslinking densities, and surface properties that allow for sustained release over extended periods. This dynamic control enables the system to adapt release characteristics to specific therapeutic needs while maintaining ease of formulation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The polymeric nanoparticles achieve high encapsulation efficiency, increased cell internalization, and sustained release of inhibitory RNAs, enabling effective delivery over extended periods, addressing the limitations of existing systems by providing a safe and efficient means to silence target genes.
Implementation Method 1
complexed with polycations, are developed to enhance encapsulation efficiency
Implementation Method 2
facilitate controlled, sustained release
Implementation Method 3
controlled delivery of inhibitory ribonucleic acids
Implementation Method 4
modifying the nanoparticle surface with coupling agents for modular assembly and disassembly of functional elements
Implementation Method 5
increased cell internalization
Data Source
AI summary
Polymeric nanoparticles encapsulating inhibitory ribonucleic acids (RNAs) and methods of their manufacture and use are provided. Advantageous properties of the nanoparticles include: 1) high encapsulation efficiency of inhibitory RNAs into the nanoparticles, 2) small size of the nanoparticles that increases cell internalization, and 3) sustained release of encapsulated inhibitory RNAs by the nanoparticles that allows for administration of an effective amount of inhibitory RNAs to cells or tissues over extended periods of time. Encapsulation efficiency of inhibitory RNAs into the nanoparticles is greatly increased by complexing the inhibitory RNAs to polycations prior to encapsulation. Methods of using the polymeric nanoparticles for treating or inhibiting diseases or disorders are provided.